Key Insights

Highlights

Treatment Research

7 treatments under study, led by Pemetrexed

Related Conditions

Often studied with 6 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

100.0%

2 terminated out of 2 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Terminated2

Clinical Trials (2)

Showing 2 of 2 trials
NCT04698681Terminated

NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial

NCT04265534Phase 2Terminated

KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC

Showing all 2 trials

Research Network

Common Treatments

  • Pemetrexed1
  • Dexamethasone1
  • Vitamin B12 1000 Μg1
  • Pembrolizumab1
  • Carboplatin1

Active Sponsors

  • Calithera Biosciences, Inc2

Top Investigators

Related Conditions

  • Nfe2l2 Gene Mutation2
  • Nonsmall Cell Lung Cancer2
  • Nonsquamous Nonsmall Cell Neoplasm Of Lung2
  • Nonsquamous Nonsmallcell Lung Cancer2
  • Nrf2 Gene Mutation1

Activity Timeline